Profile and molecular modeling of 3-(indole-3-yl)-4-(3,4,5- trimethoxyphenyl)-1H-pyrrole-2,5-dione (1) as a highly selective VEGF-R2/3 inhibitor

Journal of Medicinal Chemistry

Volumn 49, Issue 25, 2006, Pages 7549-7553

  Peifer, Christian ^a   Krasowski, Agata ^a   Hämmerle, Nina ^a   Kohlbacher, Oliver ^a   Dannhardt, Gerd ^b   Totzke, Frank ^c   Schächtele, Christoph ^c   Laufer, Stefan ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c PROQINASE GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 (INDOL 3 YL) 4 (3,4,5 TRIMETHOXYPHENYL) 1H PYRROLE 2,5 DIONE; ADENOSINE TRIPHOSPHATE; DASATINIB; ERLOTINIB; GEFITINIB; IMATINIB; PYRROLE DERIVATIVE; SORAFENIB; STAUROSPORINE; SUNITINIB; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ARTICLE; BINDING AFFINITY; DRUG ACTIVITY; DRUG SELECTIVITY; ENZYME ANALYSIS; HYDROPHOBICITY; MOLECULAR MODEL; NONHUMAN; PROTEIN STRUCTURE; PROTEIN TARGETING; SEQUENCE HOMOLOGY;

AMINO ACID SEQUENCE; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; HYDROPHOBICITY; INDOLES; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PYRROLES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 33845476023     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0609871     Document Type: Article

References (52)

1. Hopkins, A. L.; Groom, C. R. The druggable genome. Nat. Rev. Drug Discovery 2002, 1, 727-730.
2. Blume-Jensen, P.; Hunter, T. Oncogenic kinase signalling. Nature 2001, 411, 355-365.
3. Shawver, L. K.; Slamon, D.; Ullrich, A. Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 2002, 1, 117-123.
4. Kung, C.; Shokat, K. M. Small-molecule kinase-inhibitor target assessment. ChemBioChem 2005, 6, 523-526.
5. Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S. The protein kinase complement of the human genome. Science 2002, 298, 1912-1916, 1933.
6. Daub, H. Characterisation of kinase-selective inhibitors by chemical proteomics. BBA-Proteins Proteomics 2005, 1754, 183-190.
7. McGovern, S. L.; Shoichet, B. K. Kinase inhibitors: Not just for kinases anymore. J. Med. Chem. 2003, 46, 1478-1483.
8. Luo, Y. Selectivity assessment of kinase inhibitors: Strategies and challenges. Curr. Opin. Mol. Ther. 2005, 7, 251-255.
9. Fabian, M. A.; Biggs, W. H., III; Treiber, D. K.; Atteridge, C. E.; Azimioara, M. D.; Benedetti, M. G.; Carter, T. A.; Ciceri, P.; Edeen, P. T.; Floyd, M.; Ford, J. M.; Galvin, M.; Gerlach, J. L.; Grotzfeld, R. M.; Herrgard, S.; Insko, D. E.; Insko, M. A.; Lai, A. G.; Lias, J. M.; Mehta, S. A.; Milanov, Z. V.; Velasco, A. M.; Wodicka, L. M.; Patel, H. K.; Zarrinkar, P. P.; Lockhart, D. J. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 2005, 23, 329-336.
10. Knight, Z. A.; Shokat, K. M. Features of selective kinase inhibitors. Chem. Biol. 2005, 12, 621-637.
11. Kung, C.; Kenski, D. M.; Krukenberg, K.; Madhani, H. D.; Shokat, K. M. Selective kinase inhibition by exploiting differential pathway sensitivity. Chem. Biol. 2006, 13, 399-407.
12. Horiuchi, K. Y.; Wang, Y.; Diamond, S. L.; Ma, H. Microarrays for the functional analysis of the chemical-kinase interactome. J. Biomol. Screening 2006, 11, 48-56.
13. Zhang, Z.; Meier, K. E. New assignments for multitasking signal transduction inhibitors. Mol. Pharmacol. 2006, 69, 1510-1512.
14. Vieth, M.; Sutherland, J. J.; Robertson, D. H.; Campbell, R. M. Kinomics: Characterizing the therapeutically validated kinase space. Drug Discovery Today 2005, 10, 839-846.
15. Capdeville, R.; Buchdunger, E.; Zimmermann, J.; Matter, A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Discovery 2002, 1, 493-502.
16. Cappuzzo, F.; Finocchiaro, G.; Metro, G.; Bartolini, S.; Magrini, E.; Cancellieri, A.; Trisolini, R.; Castaldini, L.; Tallini, G.; Crino, L. Clinical experience with gefitinib: An update. CRC Crit. Rev. Oncol.-Hematol. 2006, 58, 31-45.
17. Leighl, N. B.; Res, D. Erlotinib: Profile report. Drugs Ther. Perspect. 2006, 22, 1-2.
18. Rini, B. I. Sorafenib. Expert Opin. Pharmacother. 2006, 7, 453-461.
19. Atkins, M.; Jones, C. A.; Kirkpatrick, P. Sunitinib maleate. Nat. Rev. Drug Discovery 2006, 5, 279-280.
20. McIntyre, J. A.; Er, J.; Bayes, M. Dasatinib. Treatment of leukemia treatment of solid tumors Bcr-Abl and Src kinase inhibitor. Drugs Future 2006, 31, 291-303.
21. Grosios, K.; Traxler, P. Tyrosine kinase targets in drug discovery. Drugs Future 2003, 28, 679-697.
22. Arora, A.; Scholar, E. M. Role of tyrosine kinase inhibitors in cancer therapy. J. Pharmacol. Exp. Ther. 2005, 315, 971-979.
23. Krause, D. S.; Van Etten, R. A. Tyrosine kinases as targets for cancer therapy. New Engl. J. Med. 2005, 353, 172-187.
24. Peifer, C.; Dannhardt, G. A novel quantitative chick embryo assay as an angiogenesis model using digital image analysis. Anticancer Res. 2004, 24, 1545-1551.
25. (a) Peifer, C.; Stoiber, T.; Unger, E.; Totzke, F.; Schächtele, C.; Marmé, D.; Brenk, R.; Klebe, G.; Schollmeyer, D.; Dannhardt, G. Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J. Med. Chem. 2006, 49, 1271-1281.
26. (b) Dannhardt, G. and Peifer, C. 3-(Indolyl)-4-arylmaleimide derivatives and their use as angiogenesis inhibitors. Patent WO 2006/061212 A1, 2006.
27. Boyer, S. J. Small molecule inhibitors of KDR (VEGFR-2) kinase: an overview of structure activity relationships. Curr. Top. Med. Chem. 2002, 2, 973-1000.
28. Kane, S. E. Cancer therapies targeted to the epidermal growth factor receptor and its family members. Expert Opin. Ther. Pat. 2006, 16, 147-164.
29. Miyazaki, Y.; Matsunaga, S.; Tang, J.; Maeda, Y.; Nakano, M.; Philippe, R. J.; Shibahara, M.; Liu, W.; Sato, H.; Wang, L.; Nolte, R. T. Novel 4-amino-furo[2,3-d]pyrimidines as Tie-2 and VEGFR2 dual inhibitors. Bioorg. Med. Chem. Lett. 2005, 15, 2203-2207.
30. Roberts, W. G.; Whalen, P. M.; Soderstrom, E.; Moraski, G.; Lyssikatos, J. P.; Wang, H. F.; Cooper, B.; Baker, D. A.; Savage, D.; Dalvie, D.; Atherton, J. A.; Ralston, S.; Szewc, R.; Kath, J. C.; Lin, J.; Soderstrom, C.; Tkalcevic, G.; Cohen, B. D.; Pollack, V.; Barth, W.; Hungerford, W.; Ung, E. Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673.-451. Cancer Res. 2005, 65, 957-966.
31. Chen, T.; Georgea, J. A.; Taylor, C. C. Src tyrosine kinase as a chemotherapeutic target: Is there a clinical case? Anti-Cancer Drugs 2006, 17, 123-131.
32. Choi, H. S.; Wang, Z.; Richmond, W.; He, X.; Yang, K.; Jiang, T.; Karanewsky, D.; Gu, X.; Zhou, V.; Liu, Y.; Che, J.; Lee, C. C.; Caldwell, J.; Kanazawa, T.; Umemura, I.; Matsuura, N.; Ohmori, O.; Honda, T.; Gray, N.; He, Y. Design and synthesis of 7H-pyrrolo-[2,3-d]pyrimidines as focal adhesion kinase inhibitors. Part 2. Bioorg. Med. Chem. Lett. 2006, 16, 2689-2692.
33. Choi, H. S.; Wang, Z.; Richmond, W.; He, X.; Yang, K.; Jiang, T.; Sim, T.; Karanewsky, D.; Gu, X. J.; Zhou, V.; Liu, Y.; Ohmori, O.; Caldwell, J.; Gray, N.; He, Y. Design and synthesis of 7H-pyrrolo-[2,3-d]pyrimidines as focal adhesion kinase inhibitors. Part 1. Bioorg. Med. Chem. Lett. 2006, 16, 2173-2176.
34. Brantley-Sieders, D. M.; Chen, J. Eph receptor tyrosine kinases in angiogenesis: From development to disease. Angiogenesis 2004, 7, 17-28.
35. Menu, E.; Jernberg-Wiklund, H.; Stromberg, T.; De Raeve, H.; Girnita, L.; Larsson, O.; Axelson, M.; Asosingh, K.; Nilsson, K.; Van Camp, B.; Vanderkerken, K. Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: An in vitro and in vivo study in the 5T33MM mouse model. Blood 2006, 107, 655-660.
36. Wong, S.; Witte, O. N. The BCR-ABL story: Bench to bedside and back. Annu. Rev. Immunol. 2004, 22, 247-306.
37. Yee, D. Targeting insulin-like growth factor pathways. Br. J. Cancer 2006, 94, 465-468.
38. McInnes, C.; Mezna, M.; Fischer, P. M. Progress in the discovery of Polo-like kinase inhibitors. Curr. Top. Med. Chem. 2005, 5, 181-197.
39. Blagden, S.; de Bono, J. Drugging cell cycle kinases in cancer therapy. Curr. Drug Targets 2005, 6, 325-335.
40. Smalley, J.; Peat, A. J.; Boucheron, J. A.; Dickerson, S.; Garrido, D.; Preugschat, F.; Schweiker, S. L.; Thomson, S. A.; Wang, T. Y. Synthesis and evaluation of novel heterocyclic inhibitors of GSK-3. Bioorg. Med. Chem. Lett. 2006, 16, 2091-2094.
41. Hayward, D. G.; Clarke, R. B.; Faragher, A. J.; Pillai, M. R.; Hagan, I. M.; Fry, A. M. The centrosomal kinase Nek2 displays elevated levels of protein expression in human breast cancer. Cancer Res. 2004, 64, 7370-7376.
42. Matthews, N.; Visintin, C.; Hartzoulakis, B.; Jarvis, A.; Selwood, D. L. Aurora A and B kinases as targets for cancer: Will they be selective for tumors? Expert Rev. Anticancer Ther. 2006, 6, 109-120.
43. Garcia-Sosa, A. T.; Mancera, R. L. The effect of a tightly bound water molecule on scaffold diversity in the computer-aided de novo ligand design of CDK2 inhibitors. J. Mol. Model. 2006, 12, 422-431.
44. Harris, P. A.; Cheung, M.; Hunter, R. N., III; Brown, M. L.; Veal, J. M.; Nolte, R. T.; Wang, L.; Liu, W.; Crosby, R. M.; Johnson, J. H.; Epperly, A. H.; Kumar, R.; Luttrell, D. K.; Stafford, J. A. Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J. Med. Chem. 2005, 48, 1610-1619.
45. Nowakowski, J.; Cronin, C. N.; McRee, D. E.; Knuth, M. W.; Nelson, C. G.; Pavletich, N. P.; Rogers, J.; Sang, B. C.; Scheibe, D. N.; Swanson, R. V.; Thompson, D. A. Structures of the cancer-related Aurora-A, FAK, and EphA2 protein kinases from nanovolume crystallography. Structure 2002, 10, 1659-1667.
46. Olsson, A. K.; Dimberg, A.; Kreuger, J.; Claesson-Welsh, L. VEGF receptor signalling-in control of vascular function. Nat. Rev. Mol. Cell Biol. 2006, 7, 359-371.
47. Wiedmann, M. W.; Caca, K. Molecularly targeted therapy for gastrointestinal cancer. Curr. Cancer Drug Targets 2005, 5, 171-193.
48. Zareba, G.; Castaner, J.; Bozzo, J. Vandetanib. Angiogenesis inhibitor VEGFR inhibitor. Drugs Future 2005, 30, 138-145.
49. Rarey, M.; Kramer, B.; Lengauer, T.; Klebe, G. A fast flexible docking method using an incremental construction algorithm. J. Mol. Biol. 1996, 261, 470-489.
50. Gohlke, H.; Hendlich, M.; Klebe, G. Knowledge-based scoring function to predict protein-ligand interactions. J. Mol. Biol. 2000, 295, 337-356.
51. Goodford, P. J. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J. Med. Chem. 1985, 28, 849-857.
52. Moll, A.; Hildebrandt, A.; Lenhof, H. P.; Kohlbacher, O. BALL-View: An object-oriented molecular visualization and modeling framework. J. Comput.-Aided Mol. Des. 2005, 19, 791-800.